QNTM

6-K - Quantum Biopharma Ltd. (0001771885) (Filer)

6-K - Quantum Biopharma Ltd. (0001771885) (Filer)

SCHEDULE 13G/A - Quantum Biopharma Ltd. (0001771885) (Subject)

AUSTIN, Texas, Sept. 30, 2026 (GLOBE NEWSWIRE) --  via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The BioMedWire Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels. The BioMedWire Podcast delivers dynamic interviews with industry experts at the forefront of pharmaceutical and biotech advancement. The latest episode features the return of Anthony Durkacz, Co-Founder and Executive Co-Chair of Quantum BioPharma Ltd. (NASDAQ:QNTM), a biopharmaceutical company dedicated to building a portf

6-K - Quantum Biopharma Ltd. (0001771885) (Filer)

TORONTO, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ:QNTM) (FRA: 0K91) ("Quantum BioPharma"), today announced its licensee – Unbuzzd Wellness Inc. (the "Company" or "Unbuzzd"), the company behind unbuzzd™ ("unbuzzd") — the scientifically-proven and game-changing beverage proven to accelerate alcohol metabolism, restore mental clarity and reduce hangover symptoms, is pleased to announce the appointment of Mr. Michael Zapolin ("Zappy") as CEO. This marks a pivotal milestone in the Company. His mandate includes financing and listing Unbuzzd on a stock exchange and then executing a nationwide commercial marketing and product rollout in the United States. Zappy began his

6-K - Quantum Biopharma Ltd. (0001771885) (Filer)

6-K - Quantum Biopharma Ltd. (0001771885) (Filer)

TORONTO, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ:QNTM) (FRA: 0K91) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development, today announces Rodman & Renshaw has initiated coverage of Quantum BioPharma with a BUY rating and a US$8 price target. The lead analyst of this report is Michael G. King Jr., Director of Research, Senior Biotechnology Analyst at Rodman & Renshaw. This coverage is unpaid and Quantum BioPharma provi

6-K - Quantum Biopharma Ltd. (0001771885) (Filer)

NEW YORK, Sept. 11, 2026 (GLOBE NEWSWIRE) -- via BioMedWire — Quantum BioPharma Ltd. (NASDAQ:QNTM) today announces its placement in an editorial published by BioMedWire (BMW), one of 75+ brands within the Dynamic Brand Portfolio@IBN (InvestorBrandNetwork), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. To view the full publication, "Historic First in MS Treatment Could Reshape a Multibillion-Dollar Therapeutics Market," please visit: https://ibn.fm/HOCTP Today’s multiple sclerosis ("MS") treatments can slow down disease progression, but none of them halt it outright, and none gi

AUSTIN, Texas, Sept. 10, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Today's multiple sclerosis treatments can slow down disease progression, but none of them halt it outright, and none give back the function patients have already lost. Close to a million people in the United States, and nearly 2.9 million worldwide, live with that reality, watching a condition that steadily chips away at mobility, eyesight and basic physical control. That gap in treatment options just picked up a serious new contender. Quantum BioPharma Ltd. (NASDAQ:QNTM) (profile) has received U.S. Food and Drug Administration ("FDA") clearance to launch a phase 2 trial of Lucid-MS, a patented, first-in-class

NEW YORK, Sept. 09, 2026 (GLOBE NEWSWIRE) -- via BioMedWire — Quantum BioPharma Ltd. (NASDAQ:QNTM) (CSE:QNTM) today announces its placement in an editorial published by BioMedWire (BMW), one of 75+ brands within the Dynamic Brand Portfolio@IBN (InvestorBrandNetwork), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. To view the full publication, "A Micro-Cap Biotech Just Cleared a Milestone Most Never Reach," please visit: https://ibn.fm/b9zkB Multiple sclerosis ("MS") drugs on the market today can slow the disease down, but none of them stop it, and none of them give patients back

6-K/A - Quantum Biopharma Ltd. (0001771885) (Filer)

6-K/A - Quantum Biopharma Ltd. (0001771885) (Filer)

6-K/A - Quantum Biopharma Ltd. (0001771885) (Filer)

AUSTIN, Texas, Sept. 08, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Multiple sclerosis ("MS") drugs on the market today can slow the disease down, but none of them stop it, and none of them give patients back what they have already lost. Nearly one million people in the United States, and close to 2.9 million worldwide, live with that reality, watching a disease that can gradually erode mobility, vision, and basic bodily control. That gap has just gotten a serious new challenger. Quantum BioPharma Ltd. (NASDAQ:QNTM) (profile) has received FDA clearance to begin a phase 2 trial of Lucid-MS, a patented, first-in-class drug candidate aimed not at calming the immune system but at

6-K - Quantum Biopharma Ltd. (0001771885) (Filer)

THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES. TORONTO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ:QNTM) (CSE:QNTM) (FSE: 0K91) (Upstream: QNTM) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development, announces that it has applied for a voluntary delisting of its Class B subordinate voting shares

Rodman & Renshaw initiated coverage of Quantum BioPharma Ltd with a rating of Buy and set a new price target of $8.00

THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES. TORONTO, Aug. 21, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ:QNTM) (CSE:QNTM) (FRA: 0K91) ("Quantum" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, is pleased to announce the following corporate update. The Company announces the grant of an aggregate of 572,500 stock options (the "Stock Options") to certain directors, officers, employees and consultants of the Company. Each Stock Option is exercisable at a price of C$4.80 for a

6-K - Quantum Biopharma Ltd. (0001771885) (Filer)

6-K - Quantum Biopharma Ltd. (0001771885) (Filer)

6-K/A - Quantum Biopharma Ltd. (0001771885) (Filer)

6-K - Quantum Biopharma Ltd. (0001771885) (Filer)